Fairfield, Bush & Co’s Sage Therapeutics SAGE Stock Holding History

Fairfield, Bush & Co’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,000	Closed	-$235K	–	420
2023 Q2	$235K	Hold	5,000	–	–	0.06%	139
2023 Q1	$210K	Buy	+5,000	New	+$215K	0.07%	137
2021 Q4	–	Sell	-5,000	Closed	-$222K	–	158
2021 Q3	$222K	Buy	+5,000	New	+$229K	0.07%	152
2021 Q2	–	Sell	-5,000	Closed	-$374K	–	161
2021 Q1	$374K	Hold	5,000	–	–	0.11%	129
2020 Q4	$433K	Hold	5,000	–	–	0.13%	111
2020 Q3	$306K	Hold	5,000	–	–	0.1%	118
2020 Q2	$208K	Buy	+5,000	New	+$181K	0.07%	132

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fairfield, Bush & Co's SAGE Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 5,000 shares — an estimated $235K sold.

Fairfield, Bush & Co first reported a position in SAGE in Q2 2020 and held it in 7 quarters. The position peaked at $433K in Q4 2020. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Fairfield, Bush & Co reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Fairfield, Bush & Co sold 5,000 Sage Therapeutics shares in Q3 2023, an estimated $235K.
Fairfield, Bush & Co first reported a position in Sage Therapeutics in Q2 2020 and held it in 7 quarters.
Fairfield, Bush & Co's Sage Therapeutics position peaked at $433K in Q4 2020.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.